Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus BCG vs BCG alone in high-risk BCG-naive non-muscle invasive bladder cancer
jRCT2080223911Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) comparing Durvalumab plus BCG with BCG alone (standard of care) (2 arms). Started May 2018; status: completed.
02
Drugs
durvalumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2080223911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223911.